Trial Profile
A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Prednisone (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms RIFLE
- Sponsors AMPEL BioSolutions
- 07 Jul 2020 Status changed from active, no longer recruiting to completed.
- 30 Nov 2018 Planned End Date changed from 1 Dec 2018 to 1 Jul 2019.
- 30 Nov 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Apr 2019.